pegylated liposomal doxorubicin + SL-172154

Pegylated liposomal doxorubicin (PLD) is a formulation of the anthracycline antibiotic and antineoplastic agent doxorubicin, encapsulated in a pegylated liposome to improve pharmacokinetics and reduce toxicity. It works by intercalating DNA, inhibiting topoisomerase II, and generating free radicals that damage cellular components, leading to cell death. PLD is approved for use in ovarian cancer that has recurred after platinum-based chemotherapy[3][4]. SL-172154 is an investigational Agonist Redirected Checkpoint (ARC) fusion protein developed by Shattuck Labs. It simultaneously inhibits the CD47/SIRPα checkpoint interaction—blocking a "don't eat me" signal on tumor cells—and activates the CD40 costimulatory receptor to stimulate anti-tumor immune responses[1][2][5][6]. The combination of PLD with SL-172154 is being studied in clinical trials for patients with advanced cancers such as platinum-resistant ovarian cancer and acute myeloid leukemia (AML), aiming to enhance both direct cytotoxicity against tumor cells and immune-mediated anti-tumor activity[4][5].

Brand names

Doxil

Other names

PLDpegylated liposomal doxorubicindoxorubicin hydrochloride liposome injection